HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

被引:320
作者
Campoli, M. [3 ]
Ferrone, S. [1 ,2 ]
机构
[1] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Inst Canc, Dept Pathol & Immunol, Pittsburgh, PA 15213 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80202 USA
关键词
antigen processing machinery; cancer; HLA antigen; epigenetic; immune escape; NK cell-activating ligand;
D O I
10.1038/onc.2008.273
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0-90%, are caused by distinct mechanisms. They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modi. cations that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modi. cations can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modi. cations underlying changes in HLA antigen expression in malignant cells have been discussed.
引用
收藏
页码:5869 / 5885
页数:17
相关论文
共 133 条
[1]   Rational development of histone deacetylase inhibitors as anticancer agents: A review [J].
Acharya, MR ;
Sparreboom, A ;
Venitz, J ;
Figg, WD .
MOLECULAR PHARMACOLOGY, 2005, 68 (04) :917-932
[2]   Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? [J].
Altomonte, M ;
Fonsatti, E ;
Visintin, A ;
Maio, M .
ONCOGENE, 2003, 22 (42) :6564-6569
[3]   Activation of natural killer cells:: Underlying molecular mechanisms revealed [J].
Backström, E ;
Kristensson, K ;
Ljunggren, HG .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2004, 60 (1-2) :14-22
[4]   Arginine methylation: An emerging regulator of protein function [J].
Bedford, MT ;
Richard, S .
MOLECULAR CELL, 2005, 18 (03) :263-272
[5]   Phylogenetic shadowing and computational identification of human microRNA genes [J].
Berezikov, E ;
Guryev, V ;
van de Belt, J ;
Wienholds, E ;
Plasterk, RHA ;
Cuppen, E .
CELL, 2005, 120 (01) :21-24
[6]   On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases [J].
Bernsen, MR ;
Håkansson, L ;
Gustafsson, B ;
Krysander, L ;
Rettrup, B ;
Ruiter, D ;
Håkansson, A .
BRITISH JOURNAL OF CANCER, 2003, 88 (03) :424-431
[7]   Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies [J].
Bhalla, KN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3971-3993
[8]   How do CD4+CD25+ regulatory T cells control autoimmunity? [J].
Bluestone, JA ;
Tang, QZ .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (06) :638-642
[9]   DNA methylation of retinoic acid receptor β in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine [J].
Bovenzi, V ;
Lê, NLO ;
Cóté, S ;
Sinnett, D ;
Momparler, LF ;
Momparler, RL .
ANTI-CANCER DRUGS, 1999, 10 (05) :471-476
[10]   BIOLOGICAL IMPLICATIONS OF HLA-DR EXPRESSION IN TUMORS [J].
CABRERA, T ;
RUIZCABELLO, F ;
GARRIDO, F .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (04) :398-406